Bioasis Technologies Inc. V.BTI

$5.25 million

[prophetoffactz]

BTI received $5.25 million upfront for 4 LSDs.

If there is a way out of BTI's predicament that doesn't issue shares what could it look like?

If BTI sold 4 LSDs to Chiesi and XOMA for $5.25 million upfront what could BTI sell the remaining value of the Chiesi deal back to Chiesi for and how much upfront could BTI receive for selling Chiesi 100% control of the remmaining LSD opportunities(eg. Hunter, Gauchers)? 

What could BTI receive upfront from J&J for 100% ownership for its multi-product xB3 applications? Or upfront from XOMA?

100% to Neuramedy?

100% Herceptin?

[Boomskid]

Hah, poof, thank you for recognizing the LSD deal I have proposed for years. I proposed selling the entire rights to LSDs for $30 million to $50 million, all in, no royalties, possibly enough to get xB3-001 through phase 1b/2. My guess is that Bioasis would have to include all rights to xB3-004 to get half that much now ($15 million to $25 million). Chiesi stuck it to Bioasis during hard times

[prophetoffactz]

Chiesi is into rare diseases. It could sell the LSD franchine and also enter a deal on EGF. 

[Boomskid]

Yes, poof, Chiesi Global Rare Diseases is in the rare disease business. There are so many companies that claim to be in the rare disease space that the term has lost most of its meaning. And, yes, Chiesi, take the EGF stuff. The Midatech "merger" valued the Cresence stuff at $250,000. Then Bioasis would have to focus on advancing xB3, what the company should have been doing for the

[prophetoffactz]

BTI could sell the upfront EGF opportunities for upfront cash and keep the xB3 applications. BTI is potentially opportunity rich at $.02 and this may provide a surprise escape. 

[Boomskid]

Yes, poof, I agree. Sell the EGF stuff. Bioasis might get enough to make a couple of payments on the Lind convertible debt. Remember that the EGF things that are "clinic ready" are not xB3 drugs. CNS xB3 versions of EGF are years away. Sell 'em. Give' em away.  There are bigger, better things to pursue. And Bioasis needs to forget "clinic ready" and NASDAQ for a

[prophetoffactz]

"$3 million up front and only $138 million in milestone payments for 4 LSDs." You don't mention the potential royalties on C$1.5 billion at peak sales, or whatever.   

[Boomskid]

Royalties? From Chiesi?  They haven't even produced a developmental or regulatory milestone payment yet, let alone a commercial milestone or royalty payment. C$1.5 billion in royalties? Of course I haven't mentioned them. I save the silly stuff for you, poof.  jd

[homerun2010]

This would be quite a feat for management if it were focused on salvaging something for shareholders.  The company has: Zero asset value Zero shareholder equity Why license something for three million plus future financial obligations where you could offer $3 million to own a company worth $1.6 million? Are shareholder's in possession of all material info on the technology?  Or

[prophetoffactz]

For us on the outside this is a black box. We don't know what the result will be. Biotech licensees operates in secret. What is the residual value of the Chiesi deal for xB3 less what was sold to XOMA? Chiesi recently secured FDA approval for one enzyme and a positive opinion from EU regulators for Fabry that BTI may have licensed for. It could be headed to full FDA and European approval

[homerun2010]

Much of what is said here is very material to BTI if true and must be disclosed to the markets and shareholders if it positively or negatively affects the impending financial status of the company Failure to disclose, would be a serious infraction; especially, if the IP or other technology owned by shareholders is sold or licensed at prices or terms disadvantageous to the owners,  the

[fuzzyjr]

Somethings got to give soon. glts 

[prophetoffactz]

It will be interesting. Is BTI a zero or hero? There are a number of different possibilities to add value at $.02 as has been outlined. I originally hoped for a Saltarelli - a deal consistent with Saltarelli's historic success. He's chosen to stay with BTI when he could easily go elsewhere. He's said xB3 should be able to perform equal to or better than DNLI. We have the validation

[unclepieman]

I suspect and anticipate a Zero! This company lasted about 10y longer than it should have, being a micro pharma scam. It is what it is, I rolled the dice and sometimes ... you get snake eyes and you walk away!

[zwerp2000]

This post has been removed in accordance with Community Policy

[fuzzyjr]

ya he's wrong. To much of a coward to face the Rath - he's got a bag full of hot air, no shares & mad like 2 year old